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Background: Osteopenia and osteoporosis has been observed
requently in HIV-infected adolescents. Vitamin D deﬁciency may
e a contributing factor. We aimed to determine the prevalence of
itamin D deﬁciency among perinatally HIV-infected Thai adoles-
ents who were receiving antiretroviral therapy (ART).
Methods:A cross-sectional studywas performed in adolescents
ith perinatal HIV infection. Vitamin D level, parathyroid hormone
nd calcium were measured in blood. Vitamin D deﬁciency was
eﬁned as levels of 25-(OH)- vitamin D below 20 ng/ml and insufﬁ-
iency as 20-30 ng/ml. The information of dietary consumption and
unlight exposure were collected by self report structured ques-
ionnaire.
Results: 101 adolescents, 50% male, median age 14.3 (range,
2.0-19.5) years, were enrolled. Median (IQR) duration of ART was
3.9 (52.2-104.2)months. 90% of children had plasmaHIV RNA<50
opies/ml in the past 6 months. The median vitamin D level was
4.8 (range, 6.9-46.9) ng/ml. Twenty-ﬁve patients (25%) had 25-
OH)- vitamin D level < 20 ng/ml and twenty-nine patients (29%)
ad level of 20-30 ng/ml. The median parathyroid hormone was
4 (range,15.4-121.6) ng/L. Patients with vitamin D deﬁciency had
igher parathyroid hormone level [13.3(3.2-55.6),P <0.001]. There
as no signiﬁcant difference in serum calcium level or hours of
xposure to sunlight between the patients with or without vitamin
deﬁciency.
Conclusion: Half of the HIV-infected adolescents were found toave insufﬁciency or deﬁciency of vitamin D. Preventive measures
hould be included in routine care.
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Comparison of anti-HIV-1 neutralizing activity between the
plasma derived fromHIV-1 infected, slow and rapid progressors
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Background: Neutralizing antibodies (NAb) are a critical com-
ponent of the protective immunity required for developing an
effective HIV-1 vaccine; however, an HIV-1 vaccine has not been
succeeded. Plasmaof someHIV-1-infectedpatients contains potent
and broadly reactive NAb, and the understanding of how such
antibodies are elicited may provide valuable insights to develop
effective HIV-1 vaccine. CRF01 AE, a major CRF, accounts for more
than 80% of HIV-1 infections in Thailand. Envelope glycoprotein
(Env) is amajor target of anti-HIV-1neutralizing antibodies, but has
a high level of inter-subtype heterogeneity; therefore, the humoral
immune responses against Env potentially vary among different
HIV-1 subtypes and CRFs.
Methods: In order to study the impact of humoral immune
response to HIV-1 CRF01 AE Env on the course of disease progres-
sion, we examined an anti-HIV-1 neutralizing activity of plasma
derived from 34 slow (CD4 >100 cells/cm3 at the time of enroll-
ment, healthy at least 8 years without antiretroviral treatment)
and 33 rapid (CD4 >100 cells/cm3 at the time of enrollment, died
with AIDS symptom within 5 years) progressors residing in north-
ern Thailand. High throughput neutralization test was performed
using CRF01 AE Env-recombinant, luciferase reporter viruses.
Results: The level of neutralizing activity varied considerably
among patients plasma, and no clear differences in potency and
breadth of anti-HIV-1 neutralizing activity was observed between
the plasma derived from rapid and slow progressors. However,
plasmaderived from4 slowprogressors showedneutralizing activ-
ity against all recombinant viruses tested, whereas none of plasma
fromrapidprogressors showed such abroadlyneutralizing activity.
The broadly neutralizing plasma derived from 4 slow progressors
did not show strong neutralizing activity to clade B and clade C Env
clones.
Conclusion: Although no clear differences in the extent of
anti-HIV-1 neutralizing activity was observed between the plasma
derived from rapid and slow progressors, some of slow progressor-
derived plasma showed CRF01 AE speciﬁc broadly neutralizing
activity. These results suggest that anti-HIV-1 humoral immune
responses affect, at least in part, on the disease progression. We
plan to examine the epitopes of neutralizing antibodies in these
patients’ plasma with a broad and potent neutralizing activity.
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